Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
NCT04925193Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Nov 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by University of Colorado Denver. Primary endpoint: Overall Response Rate at 10 months. Started Nov 2021; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04925193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925193.